retatrutide ly3437943 glp-1 gip glucagon Reta clinical trial data & dosing — a must read (Reta) isn't just another GLP-1. It's a triple-agonist peptide studied in Phase 3 trials for metabolic health — targeting GLP-1, Semaglutide - PRAMAH / THE

Regulatory bodies should consider targeted enforcement against false advertising and implement clearer labeling and import restrictions for products containing synthetic melanocortin analogs

Its not about fairness or healing, its about saving money

Novo initially held an advantage over Lilly, as WEGOVY entered the market before Lillys competing drug, ZEPBOUND, and secured broader insurance coverage early on

In the post-CVOT era, people living with T2D are now able to benefit from treatments that can provide a therapeutic effect across the cardio-renal metabolic axis of T2D, while their physicians have options to achieve clinically meaningful reductions in CV, HF and renal outcomes, and even to reduce mortality (Fig